Trial · NCT02367651
Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma
NCT02367651, Phase 2, Withdrawn, GlaxoSmithKline
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma. Trials, record NCT02367651. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02367651
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma
- NCT number
- NCT02367651
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- GlaxoSmithKline
- Conditions
- Sarcoma, Soft Tissue
- Interventions
- Pazopanib 800 mg, Placebo
- First posted
- 2015-02-20
- Last updated
- 2016-10-12
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) | At Day 57 and every 8 weeks thereafter until disease progression or death (assessed up to 2 years) | PFS is defined as time from randomization to development of disease progression or death due to any cause. Disease progression will be evaluated based on investigators' radiologic assessments by Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1 |
| Secondary | Overall survival (OS) | At Day 57, then every 8 weeks until disease progression, and every 3 months thereafter until death (assessed up to 2 years) | OS is defined as time from randomization to death due to any cause. |
| Secondary | Disease control rate (DCR) | At 4 months after randomization | DCR is defined as percentage of complete response + partial response + stable disease at 4 months after randomization based on RECIST version 1.1. |
| Secondary | Safety and tolerability as assessed by physical examination findings | From Day 1 up to end of treatment (assessed up to 2 years) | A brief physical examination will include height (baseline only), body weight and evaluation of the subject's medical conditions |
| Secondary | Safety and tolerability as assessed by temperature measurement | From Day 1 up to end of treatment (assessed up to 2 years) | |
| Secondary | Safety and tolerability as assessed by systolic and diastolic blood pressure measurement | From Day 1 up to end of treatment (assessed up to 2 years) | |
| Secondary | Safety and tolerability as assessed by pulse rate measurement | From Day 1 up to end of treatment (assessed up to 2 years) | |
| Secondary | Safety and tolerability as assessed by composite of clinical laboratory tests | From Day 1 up to end of treatment (assessed up to 2 years) | Clinical laboratory tests will include chemistry and hematology parameters |
| Secondary | Safety and tolerability as assessed by cardiac assessments | From Day 1 up to end of treatment (assessed up to 2 years) | Cardiac assessments will include twelve-lead electrocardiogram (ECG), echocardiogram (ECHO) or multigated angiogram (MUGA) assessments |
| Secondary | Safety and tolerability as assessed by number of subjects with adverse event | From Day 1 up to end of treatment (assessed up to 2 years) |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02367651
GET https://conductscience.org/api/trials/v1/NCT02367651/registered